A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients.

Piringer, G, Fridrik, M, Fridrik, A, Leiherer, A, Zabernigg, A, Greil, R, Eisterer, W, Tschmelitsch, J, Lang, A, Frantal, S, Burgstaller, S, Gnant, M, Thaler, J. Support Care Cancer. 2018, 26(4):1345-1352.

A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) – AGMT_CMML-1.

Burgstaller, S, Stauder, R, Kuehr, T, Lang, A, Machherndl-Spandl, S, Mayrbaeurl, B, Noesslinger, T, Petzer, A, Valent, P, Greil, R, Thaler, J. Leuk Lymphoma. 2018, 59(5):1121-1126.

Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia.

Gassner, FJ, Schubert, M, Rebhandl, S, Spandl, K, Zaborsky, N, Catakovic, K, Blaimer, S, Hebenstreit, D, Greil, R, Geisberger, R. Mol Cancer Res. 2018, 16(3):428-438.

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.

Domenyuk, V, Gatalica, Z, Santhanam, R, Wei, XX, Stark, A, Kennedy, P, Toussaint, B, Levenberg, S, Wang, J, Xiao, NQ, Greil, R, Rinnerthaler, G, Gampenrieder, SP, Heimberger, AB, Berry, DA, Barker, A, Quackenbush, J, Marshall, JL, Poste, G, Vacirca, JL, Vidal, GA, Schwartzberg, LS, Halbert, DD, Voss, A, Magee, D, Miglarese, MR, Famulok, M, Mayer, G, Spetzler, D. Nat Commun. 2018, 9(1):1219.

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.

Gampenrieder, SP, Rinnerthaler, G, Hackl, H, Pulverer, W, Weinhaeusel, A, Ilic, S, Hufnagl, C, Hauser-Kronberger, C, Egle, A, Risch, A, Greil, R. THERANOSTICS. 2018, 8(8): 2278-2288.

Factor VII deficiency in major artery occlusion stroke.

Pikija, S, Gampenrieder, SP, Millesi, K, Pilz, G, Weis, S, Mutzenbach, JS. Am J Hematol. 2018, 93(6):843-845.

Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment.

Bachmayer, S, Fastner, G, Vaszi, A, Iglseder, W, Kopp, P, Holzinger, J, Dinnewitzer, A, Rinnerthaler, G, Gampenrieder, SP, Emmanuel, K, Greil, R, Sedlmayer, F, Zehentmayr, F. Strahlenther Onkol. 2018, 194(7):62-637.

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle, A, Steurer, M, Melchardt, T, Weiss, L, Gassner, FJ, Zaborsky, N, Geisberger, R, Catakovic, K, Hartman, TN, Pleyer, L, Voskova, D, Thaler, J, Lang, A, Girschikofsky, M, Petzer, A, Greil, R. Ann Hematol. 2018.

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.

Paschka, P, Schlenk, RF, Weber, D, Benner, A, Bullinger, L, Heuser, M, Gaidzik, VI, Thol, F, Agrawal, M, Teleanu, V, Lubbert, M, Fiedler, W, Radsak, M, Krauter, J, Horst, HA, Greil, R, Mayer, K, Kundgen, A, Martens, U, Heil, G, Salih, HR, Hertenstein, B, Schwanen, C, Wulf, G, Lange, E, Pfreundschuh, M, Ringhoffer, M, Girschikofsky, M, Heinicke, T, Kraemer, D, Gohring, G, Ganser, A, Dohner, K, Dohner, H. LEUKEMIA. 2018, 32(7): 1621-1630.

A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer.

Greil, R, Greil-Ressler, S, Weiss, L, Schönlieb, C, Magnes, T, Radl, B, Bolger, GT, Vcelar, B, Sordillo, PP. Cancer Chemother Pharmacol. 2018.